KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $249.2 million.

  • Emergent BioSolutions' Cash & Current Investments rose 5933.5% to $249.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.2 million, marking a year-over-year increase of 5933.5%. This contributed to the annual value of $105.6 million for FY2024, which is 546.11% down from last year.
  • Emergent BioSolutions' Cash & Current Investments amounted to $249.2 million in Q3 2025, which was up 5933.5% from $271.0 million recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Cash & Current Investments registered a high of $642.6 million during Q4 2022, and its lowest value of $71.0 million during Q2 2024.
  • For the 5-year period, Emergent BioSolutions' Cash & Current Investments averaged around $287.2 million, with its median value being $249.2 million (2025).
  • As far as peak fluctuations go, Emergent BioSolutions' Cash & Current Investments tumbled by 8261.75% in 2023, and later skyrocketed by 28169.01% in 2025.
  • Over the past 5 years, Emergent BioSolutions' Cash & Current Investments (Quarter) stood at $576.3 million in 2021, then rose by 11.5% to $642.6 million in 2022, then plummeted by 82.62% to $111.7 million in 2023, then dropped by 5.46% to $105.6 million in 2024, then skyrocketed by 135.98% to $249.2 million in 2025.
  • Its last three reported values are $249.2 million in Q3 2025, $271.0 million for Q2 2025, and $152.8 million during Q1 2025.